Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025
Scilex Holding Company (SCLX) has announced a change in the record date for its previously declared preferred stock dividend. The dividend, which represents up to 10% of Scilex's ownership interest in its wholly owned subsidiary Semnur Pharmaceuticals, will now have a record date of April 11, 2025, instead of the previously announced January 28, 2025.
The payment date will be determined by the Board of Directors within 60 days following the new record date. The company maintains the right to further adjust the record date if necessary. Scilex continues to focus on its core business of non-opioid pain management products and its planned joint venture with IPMC Company for neurodegenerative and cardiometabolic disease treatments.
Scilex Holding Company (SCLX) ha annunciato una modifica della data di registrazione per il suo precedente dividendo sulle azioni privilegiate. Il dividendo, che rappresenta fino al 10% dell'interesse di proprietà di Scilex nella sua controllata Semnur Pharmaceuticals, avrà ora una data di registrazione fissata per il 11 aprile 2025, invece della data precedentemente annunciata del 28 gennaio 2025.
La data di pagamento sarà determinata dal Consiglio di Amministrazione entro 60 giorni dalla nuova data di registrazione. L'azienda si riserva il diritto di modificare ulteriormente la data di registrazione se necessario. Scilex continua a concentrarsi sul suo core business di prodotti per la gestione del dolore non oppioidi e sulla sua joint venture pianificata con IPMC Company per i trattamenti delle malattie neurodegenerative e cardiometaboliche.
Scilex Holding Company (SCLX) ha anunciado un cambio en la fecha de registro para su dividendo de acciones preferentes previamente declarado. El dividendo, que representa hasta el 10% del interés de propiedad de Scilex en su filial Semnur Pharmaceuticals, tendrá ahora una fecha de registro del 11 de abril de 2025, en lugar de la fecha previamente anunciada del 28 de enero de 2025.
La fecha de pago será determinada por la Junta Directiva dentro de los 60 días siguientes a la nueva fecha de registro. La empresa se reserva el derecho de ajustar aún más la fecha de registro si es necesario. Scilex continúa enfocándose en su negocio principal de productos para el manejo del dolor no opioides y en su empresa conjunta planificada con IPMC Company para tratamientos de enfermedades neurodegenerativas y cardiometabólicas.
Scilex Holding Company (SCLX)는 이전에 발표된 우선주 배당금의 기록일 변경을 발표했습니다. 이 배당금은 Scilex가 전액 소유한 자회사 Semnur Pharmaceuticals에 대한 소유 지분의 최대 10%를 나타내며, 이제 기록일은 2025년 4월 11일로 변경되었습니다. 이전에 발표된 2025년 1월 28일에서 변경된 것입니다.
지급일은 새로운 기록일로부터 60일 이내에 이사회에 의해 결정됩니다. 회사는 필요할 경우 기록일을 추가로 조정할 권리를 보유합니다. Scilex는 비오피오이드 통증 관리 제품의 핵심 사업과 IPMC Company와의 신경퇴행성 및 심혈관 대사 질환 치료를 위한 계획된 합작 투자에 계속 집중하고 있습니다.
Scilex Holding Company (SCLX) a annoncé un changement de la date d'enregistrement pour son dividende sur actions privilégiées précédemment déclaré. Le dividende, qui représente jusqu'à 10% de l'intérêt de propriété de Scilex dans sa filiale à part entière Semnur Pharmaceuticals, aura désormais une date d'enregistrement fixée au 11 avril 2025, au lieu de la date précédemment annoncée du 28 janvier 2025.
La date de paiement sera déterminée par le Conseil d'Administration dans un délai de 60 jours suivant la nouvelle date d'enregistrement. La société se réserve le droit d'ajuster à nouveau la date d'enregistrement si nécessaire. Scilex continue de se concentrer sur son activité principale de produits de gestion de la douleur non opioïdes et sur son projet de coentreprise avec IPMC Company pour le traitement des maladies neurodégénératives et cardiométaboliques.
Scilex Holding Company (SCLX) hat eine Änderung des Stichtags für die zuvor erklärte Dividende auf Vorzugsaktien bekannt gegeben. Die Dividende, die bis zu 10% des Eigentumsinteresses von Scilex an ihrer hundertprozentigen Tochtergesellschaft Semnur Pharmaceuticals darstellt, hat nun einen Stichtag am 11. April 2025, anstelle des zuvor angekündigten 28. Januar 2025.
Das Zahlungsdatum wird vom Vorstand innerhalb von 60 Tagen nach dem neuen Stichtag festgelegt. Das Unternehmen behält sich das Recht vor, den Stichtag bei Bedarf weiter anzupassen. Scilex konzentriert sich weiterhin auf sein Kerngeschäft mit nicht-opioiden Schmerzmanagementprodukten und das geplante Joint Venture mit der IPMC Company zur Behandlung neurodegenerativer und kardiometabolischer Erkrankungen.
- Dividend distribution represents potential value for shareholders through ownership in Semnur Pharmaceuticals subsidiary
- Delay in dividend record date by over two months from original date
- Uncertainty in final payment date
PALO ALTO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company, neurodegenerative and cardiometabolic disease, today announced that its Board of Directors has approved changing the previously announced record date of January 28, 2025 for its previously announced dividend of Scilex preferred stock (the “Dividend”) to its stockholders and certain other securityholders of Scilex. The new record date for the Dividend will be April 11, 2025 (the “New Record Date”). Subject to the Board’s right to further change the New Record Date, the payment date (the “Payment Date”) will be determined by subsequent resolutions of the Board, which will be within 60 days following the New Record Date.
For more information on Scilex Holding Company, refer to www.scilexholding.com.
For more information on Semnur Pharmaceuticals, Inc., refer to www.semnurpharma.com.
For more information on Scilex Holding Company Sustainability Report, refer to www.scilexholding.com/investors/sustainability.
For more information on ZTlido® including Full Prescribing Information, refer to www.ztlido.com.
For more information on ELYXYB®, including Full Prescribing Information, refer to www.elyxyb.com.
For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com.
https://www.facebook.com/scilex.pharm
https://www.linkedin.com/company/scilex-holding-company/
About Scilex Holding Company
Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company, in neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido® (lidocaine topical system)
In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA” or “SP-102”), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system)
Scilex Holding Company is headquartered in Palo Alto, California.
About Semnur Pharmaceuticals, Inc.
Semnur Pharmaceuticals, Inc. (“Semnur”) is a clinical late-stage specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies. Semnur’s product candidate, SP-102 (SEMDEXA™), is the first non-opioid novel gel formulation administered epidurally in development for patients with moderate to severe chronic radicular pain/sciatica.
Semnur Pharmaceuticals, Inc. is headquartered in Palo Alto, California
Forward-Looking Statements
This press release and any statements made for and during any presentation or meeting concerning the matters discussed in this press release contain forward-looking statements related to Scilex and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding Scilex’s declaration and payment of the Dividend and timing thereof (including that the Board may change the New Record Date and, as a result, the Payment Date), Scilex’s proposed joint venture with IPMC Company and the potential development and commercialization of treatments for obesity, neurodegenerative, cardiometabolic disease.
Risks and uncertainties that could cause Scilex’s actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks associated with the Board’s right to change the New Record Date and/or revoke the Dividend, Scilex’s ability to consummate a joint venture or any other transaction with IPMC Company and develop and commercialize treatments for obesity, neurodegenerative, cardiometabolic disease; risks associated with the unpredictability of trading markets and whether a market will be established for Scilex’s common stock; general economic, political and business conditions; risks related to COVID-19 (and other similar disruptions); the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex will be unable to successfully market or gain market acceptance of its product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the outcome of the trials and studies for SP-102, SP-103 or SP-104 may not be successful or reflect positive outcomes; risks that the prior results of the clinical and investigator-initiated trials of SP-102 (SEMDEXA™), SP-103 or SP-104 may not be replicated; regulatory and intellectual property risks; and other risks and uncertainties indicated from time to time and other risks described in Scilex’s most recent periodic reports filed with the Securities and Exchange Commission, including Scilex’s Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent Quarterly Reports on Form 10-Q that the Company has filed or may file with the SEC, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and Scilex undertakes no obligation to update any forward-looking statement in this press release except as may be required by law.
Contacts:
Investors and Media
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303
Office: (650) 516-4310
Email: investorrelations@scilexholding.com
Website: www.scilexholding.com
SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.
ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.
Gloperba® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company.
ELYXYB® is a registered trademark owned by Scilex Holding Company.
All other trademarks are the property of their respective owners.
© 2025 Scilex Holding Company All Rights Reserved.
FAQ
When is the new record date for SCLX's preferred stock dividend?
What percentage of Semnur Pharmaceuticals ownership is included in SCLX's dividend?
When will SCLX pay the preferred stock dividend?
What type of dividend is SCLX distributing to shareholders?
